Pharmdca (@Pharmdca) header
Pharmdca (@Pharmdca) profile picture

USC Pharmacy Alumni 💊 | Full-Time Investor 📈 My posts reflect my personal investment views, not investment recommendations. Always do your own due diligence.

United States
Joined September 2013
Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)
LT position PART 1 Portfolio Positions acquired: $RNA $DAWN $SLNO $NARI $BPMC $MYOV base:0x9bba915f036158582c20b51113b925f243a1a1a1 $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML base:0x4e6c9f48f73e54ee5f3ab7e2992b2d733d0d0b07 $CMRX $RLYP $ITCI $KVUE Tech positions: In order $AMZN $META $NVDA $MSFT $SOFI $GOOGL $RDDT $MELI $APP $RKLB $INTC $IREN $NBIS $CRDO $AAOI $BE $AXON $MDB Biotech positions: $VKTX $CYTK $ARDX $HROW $MDGL $CRVS $ABVX $TMDX $RVMD $NKTR $CELC $AVR
9
8
40
60,531
Gavin Baker’s Atreides went in heavy on $NBIS in Q3. I imagine he’s sold a lot by now. When you’re managing a two-way fund, you’ve got to respect the market. But this was a pretty big statement. Huge in fact.
1
1
74
9,106
Pharmdca retweeted
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Samsung Electronics is reportedly developing custom high-bandwidth memory (HBM) for $META Meta’s in-house AI chip, with the base die expected to use Samsung Foundry’s 2nm process. - $SKHY $MU
1
3
1
22
8,136
$NVDA earnings call tomorrow won’t be the same without Jensen Huang. The numbers may speak for themselves, but his vision, confidence, and bullish outlook are the real catalysts that keep the market fired up.
6
1
32
9,333
Pharmdca retweeted
Current state of AI and markets Every major tech CEO = demand is VERY strong Financial Media & FinX = FRAUDS
10
12
327
28,814
Pharmdca retweeted
The market is pricing a 7.5% $NVDA move tomorrow🚨 And someone BIG already placed their bet 👀 $13.7M+ of NVDA calls hit our tape today, including $3.9M on Jan 2028 300 calls with the stock at 160
🤝 Paid partnership
$NVDA reports tomorrow after the close, and options are pricing a 7.5% move. The Nov 18 expiry, the first one after the report, is trading at 113.4% IV. Dec 18: 61.1% Jun 2027: 47.4% 1M IV sits at 62.3%, with an IV rank of 99. That's with chips sliding for a second day. $SMH is down 4.2% and NVDA is off 2.3%. Live from volAI's SymbolViewer. The terminal is a tap away on our profile.
18
25
1
229
54,239
Reading all these $NVDA is dead posts are quite comical. Negative sentiment at its peak can only mean one thing. 😏
2
1
14
3,736
$URGN nice reversal in stock price from pre-market session
8
6,550
Pharmdca retweeted
Oppenheimer: $VKTX $120 PT “We're encouraged by VK2735's best-in-class potential following VKTX's ObesityWeek event, where 3 leading KOLs identified treatment discontinuation and resulting weight regain as the greatest unmet needs in obesity. VK2735 could uniquely address both through every-other-week and monthly subQ maintenance dosing plus an oral option, which neither tirzepatide nor retatrutide offers.”
7
14
5
111
11,544
$CRVS Chief Business Officer Jeff Arcara bought $50k of shares this week, see new Form 4 filing corvuspharma.gcs-web.com/sta…
3
11
1
55
6,114
Meta has opened a waitlist for Muse Charm, its pocket-sized device for the Muse AI agent. A limited initial batch is expected to ship in December.
Replying to @wallstengine
Muse in a keychain: “Muse Charm”
19
26
15
303
121,756
Pharmdca retweeted
Both New York Times and Wall Street Journal fabricated parts of their coverage on Jensen Huang. And they are now alternatively denying that it was an op, and blaming it on China. What a sick joke.
175
1,240
30
8,852
90,002
BREAKING: Nvidia chip customer Megaspeed says Chinese spy Alice Huang left the company in August 2025 and has no current role
4
2
35
14,690
Pharmdca retweeted
Worth a read on the @JensenHuang affair from the CEO of Epic Games
Replying to @TimSweeneyEpic
The articles backtracked from their original incendiary, and now clearly false, claims to something more like "Jensen did lawful things that powerful people didn't like". It still appears the original claims came from a single competing Big Tech lobbyist. The reporting successfully disrupted corporate governance processes, with a running cost of $1.8 trillion in losses to American pension funds and shareholders. Here's what I fear is being lost in these articles: The proper interface between government and private citizens and their corporations is rule of law. Laws are passed, and if wrongdoing as alleged, then there's due process: an investigation followed by facts and evidence presented in open court. Due process should happen here: let the facts come out whole, and not as a trickle of dubious claims. Press takedowns full of sketchily sourced claims and backtracking narratives are not the way. It's what we see outside of the free world, and is no model for The United States of America. In particular, if the Jensen takedown succeeds on the basis of these journalistic failings, which is not by any means certain as Sam Altman's case shows, then it foreshadows an economically and institutionally ruinous new playbook to be adopted with no end in sight. Imagine a weekly stream of takedowns emerging from opportunistic alignments between corporate lobbyists and political interests which, given the new partisan split between the executive and legislative branches, will attack in all directions, undermining not only the US economy but American leadership in the world. I hope cooler heads prevail this coming week as they did not on Thursday November 12. And I urge anyone who happened to oppose Jensen, open models, and the underlying trade policies in question, to recognize that this isn't a win for "team regulation". It's a change in the game from a transparent rules-based one to a sinister new form centered around politicans and lobbyists.
247
906
25
9,967
1,063,452
Jensen Huang Discusses Comeback as $NVDA Nvidia CEO With Allies - FT
1
8
88
10,327
Cagrisema in Redefine 9...worse tolerability at lower doses than Survodutide and that's with more flexible titration. It's not as good for A1c as tirzepatide, and even the lower doses have over double the rate of SE/AE as tirzepatide. I can't see myself prescribing this often.
2
1
16
9,904
This are issues with GLP1- amylin combos. High vomit rate - here 32% with $NVO CagriSema even with a moderate dose - vs 12% with $LLy TZP top dose. Also high rate of fatigue and asthenia. These are likely big hinders to long term adherence. We will never see AEs or pub from novo redefine 4 of CagriSema vs TZP. And this is why novo has no other viable option but acquiring an asset. There are GLP1 GIP coming first from $VKTX then a year later $KLRA and Roche. Novo will not remain # 2 with this pipeline. Time is precious and each lost year can be worth tens of billions..
Cagrisema in Redefine 9...worse tolerability at lower doses than Survodutide and that's with more flexible titration. It's not as good for A1c as tirzepatide, and even the lower doses have over double the rate of SE/AE as tirzepatide. I can't see myself prescribing this often.
5
6
2
44
15,697
Pharmdca retweeted
Bombshell story. The spy narrative is collapsing already. Is there clear & convincing evidence that Alice Huang was a Chinese spy? - AG says no. (“no conclusions reached”). - CIA says no. (“not yet convinced”). - DNI says no (“not entirely accurate and over-torqued”). - Ranking Democrat on House Intelligence (incoming Chairman) says no. (“today, at least, I don’t know”). This was immediately after he was briefed. Who argues otherwise? Anonymous officials tell CNN “it strains credulity to believe that she was not acting as an agent of the Chinese government — simply by virtue of the fact that she is a successful Chinese businesswoman working with one of America’s most powerful companies.” This is their proof after a year of investigating and surveillance? That she was a “successful Chinese businesswoman”? At this point, the only crime that we know for sure happened is the leaking of the classified memo. Who did that and why? An investigation should be opened.
News: The US intel community is still working to understand the relationship between a Chinese businesswoman who had an affair with Nvidia CEO Jensen Huang and the Chinese government, with multiple sources telling CNN that the intelligence collected on her to date does not prove that she was acting as a spy for Beijing. cnn.com/2026/11/12/politics/…
2,473
5,104
955
33,108
5,542,196
TWO MAJOR NVIDIA SHAREHOLDERS HAVE WRITTEN TO THE BOARD ASKING IT TO LEAVE THE DOOR OPEN FOR JENSEN HUANG'S RETURN Brad Gerstner, chief executive of Altimeter Capital, and Gavin Baker, managing partner and chief investment officer of Atreides Management, have sent a joint letter to $NVDA board. They ask the board to pursue "a slow, measured, and deliberate process regarding the future leadership of Nvidia that leaves all options on the table, including the potential return of Jensen Huang." "There are more questions about recent events than answers," they write, warning the board to "avoid a rush to replace Jensen that undermines and thwarts the best interests of shareholders." They say the company will be "capably led in the interim by Colette Kress and team" and that the board has time to get the decision right. A petition site has also launched demanding the board reinstate Huang pending an independent investigation, under the line "thirty-three years deserve an answer." Elon Musk has joined the calls for Huang's reinstatement, according to the Washington Post. The board said earlier today it has not formally engaged any candidates and has not yet selected a search firm.
61
240
36
1,780
372,177